

Impact of multiomic spatial technologies on research



Cyril DEGLETAGNE (CRCL, Lyon) & Michel SALZET (Inserm U1192, Lille)

Presentation, through examples of projects, of spatial transcriptomics and proteomics technologies for fundamental and clinical research, combined with the analysis of these data and their integration to better understand cellular and tissue functioning.



Deadline: **June 27, 2025**

PHASE I THEORETICAL



November
19 - 21, 2025



Bordeaux

OVERVIEW OF SPATIAL TRANSCRIPTOMICS AND PROTEOMICS AND THE FUTURE CHALLENGES OF THESE TECHNOLOGIES

Isabelle FOURNIER (PRISM U1192, FRA) & Karl MECHTLER (Research Institute of Molecular Pathology, AUT)

SPATIAL PROTEOMIC AND PROTEOGENOMICS, NEW TOOLS TO DISCOVER THE HIDDEN DIMENSIONS OF BIOLOGY

Michel SALZET (PRISM U1192, FRA), Erwin M. SCHOOF (DTU, DNK), Amélie BONNEFOND (European Genomic Institute for Diabetes, FRA) & Sarah SLAVOFF (Yale University, USA)



A DEEP DIVING INTO THE POTENTIAL OF SPATIAL TRANSCRIPTOMIC TOOLS FOR YOUR RESEARCH PROJECTS

Jasmine PLUMMER (Saint Jude Children's Research Hospital, USA), Luciano MARTELOTTO (SAiGENCI, AUS), Pascal BARBRY (IPMC, FRA) & Marco GRILLO (SciLife Lab, SWE)

INTEGRATING SPATIAL MULTI OMICS DATA WITH BIOINFORMATIC AND MACHINE LEARNING ALGORITHMS

Xavier ROUCOU (Université de Sherbrooke, CAN), Arnaud DROIT (University of Laval, CAN), Remy NICOLLE (CRI, FRA) & Lennart MARTENS (Ghent University, BEL)

Inserm
Workshop **286**



PHASE II PRACTICAL



December 1-3, 2025
December 1-4, 2025



Lyon
Lille

The Phase II is an in-depth illustration of some spatial technologies highlighted during the theoretical phase. It will be divided in two sessions: one dedicated to spatial proteomics (Lille), and the other to spatial transcriptomics (Lyon). For both sessions, we aim to describe in details some technologies available in our labs, illustrate various technical steps related to sample preparation, highlight the critical points of the protocols and apply bioinformatics analyses to datasets already produced or generated during the practical phase to understand their limitations and applications for fundamental and clinical studies.

SELECTION: 8-10 trainees will be selected for each city among Phase I participants.

INFORMATION &
REGISTRATION [CLICK HERE](#)